Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Unlike older male eye cells, which showed a consistent immune response pattern, older female eye cells appeared to experience ...

Older women could be vulnerable to harmful inflammation from new gene therapies to treat incurable eye diseases, new research has found.

Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one. Macular degeneration, also known as age-related macular degeneration ...

Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...

Goldman Sachs downgraded Regenxbio (RGNX) to Neutral from Buy with a price target of $14, down from $38. The firm has questions over the ...

Ocugen (OCGN) announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410-a ...

Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with Wet Age-Related Macular Degeneration (wet AMD ...